¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dust disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • rickettsial disease
    ¸®ÄÉÂ÷º´
  • Ritter¡¯s disease
    ¸®Åͺ´
  • rolling disease
    ȸÀüº´
  • spinocerebellar disease
    ô¼ö¼Ò³úº´
  • spirochetal disease
    ½ºÇÇ·ÎÇ쟺´
  • sterility disease
    ºÒÀÓº´
  • Schilder disease
    ½Ç´õº´
  • storage disease
    ÃàÀûº´
  • systemic disease
    Àü½Åº´
  • secondary disease
    ¼Ó¹ßº´, ¼Ó¹ßÁúȯ
  • self-limited disease
    ÀڱⱹÇѺ´
  • septic disease
    ÆÐÇ÷º´
  • severe combined immunodeficiency disease
    ÁßÁõº¹Çո鿪°áÇ̺´
  • sexually transmitted disease
    ¼º¸Å°³º´, ¼ºº´
  • sickle cell disease
    ³´ÀûÇ÷±¸º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • veno-occlusive disease
    Á¤¸ÆÆó¼âº´
  • viral disease
    ¹ÙÀÌ·¯½ºº´
  • wasting disease
    ¼Ò¸ðº´
  • white-spot disease
    ¹é»öÁ¡º´
  • law of prophylaxis for infectious disease
    Àü¿°º´¿¹¹æ¹ý
  • tracer disease method
    ÃßÀûÁúº´¹æ¹ý
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • hemoglobin M disease
    Çì¸ð±Û·Îºó Mº´.
  • hemoglobin M disease
    Çì¸ð±Û·Îºó Mº´
  • hemoglobin SC disease
    Çì¸ð±Û·Îºó SC º´
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SDº´.
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SD º´
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SDº´
  • hemoglobin h disease
    Ç÷»ö¼Ò H º´
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • hemolytic disease
    ¿ëÇ÷¼º Áúȯ(¡­òðü´).
  • hemolytic disease
    ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of fetus/newborn
    žÆ/½Å»ý¾Æ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemolytic disease of newborn
    ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemorrhagic disease
    ÃâÇ÷(¼º) Áúȯ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • double vessel disease
    ÀÌÇ÷°üÁúȯ.
  • double vessel disease
    ÀÌÁß°ü»óµ¿¸ÆÁúȯ.
  • duncans disease
    ´øÄ­º´
  • duncans disease
    ´øÄ­ º´
  • dyskeratosis follicularis = Dariers disease
    ¸ð³¶¼º À̰¢È­Á¾
  • encephalitis,slow virus disease
    ½½·Î¿ì ¹ÙÀÌ·¯½º º´
  • end stage renal disease, ESRD
    ¸»±â½ÅÁúȯ
  • endemic disease
    Áö¹æº´,±â»ýdzÅ亴.
  • environmental lung disease
    È£Èí [°áÇÙ,¿¹¹æ]ȯ°æ¼º ÆóÁúȯ.
  • environmental lung disease
    È£Èí °áÇÙ,¿¹¹æÈ¯°æ¼º ÆóÁúȯ.
  • epidemic disease
    À¯Çິ(ËôÌ´ËÓ).
  • epidermal-epithelial viral disease
    Ç¥ÇÇ-»óÇǼº ¹ÙÀÌ·¯½º Áúȯ
  • epizootic hemorrhagic disease =EHD
    °¡ÃàÀ¯Ç༺ ÃâÇ÷¼º Áúȯ(˧̧ËôÌ´ËÛ̴̧ËṲ̷̂).
  • erythema infectiosum = fifth disease<³ª>
    Àü¿°¼º È«¹Ý
  • exotic disease
    ¿Ü±¹Áúȯ(ÊṲ̷̀).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
COPD Chronic Obstructive Pulmonary Disease; ¸¸¼º Æó¼â¼º ÆóÁúȯ
CTD Connective Tissue Disease
DDD Degenerative Disc Disease
DILD Diffuse Interstitial Lung Disease; ¹Ì¸¸¼º °£Áú¼º ÆóÁúȯ
DJD Degenerative Joint Disease; ÅðÇ༺ °üÀýÁúȯ
  = Degenerative Arthritis; ÅðÇ༺ °üÀý¿°
 &nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
DAI Disease Activity Index
DAS Disease Activity Score
DM Disease Management
DMARD Disease Modifying Antirheumatic Drugs
DFS Disease free
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Von Gierke's disease
    Æù ±â¿¡¸£ÄÉ º´
  • von Willebrand disease
    von Willebrand Áúȯ
  • von Willebrand's disease
    Æù ºô¸®ºê¶õÆ® º´, Æùºô·¹ºê¶õµåº´
    ¼±Ãµ¼º À¯Àü¼º ¼ÒÁú·Î, »ó¿°»öü¼º ¿ì¼º ÇüÁú·Î À¯ÀüµÇ¸ç ÃâÇ÷ ½Ã°£ÀÇ ¿¬Àå, ÀÀ°í ÀÎÀÚ 8ÀÇ °áÇÌÀ» Ư¡À¸·Î ÇÑ´Ù. ºñ ÃâÇ÷°ú °ü·ÃÀÌ ÀÖÀ¸¸ç ¿Ü»ó ȤÀº ¼ö¼ú ÈÄÀÇ ÃâÇ÷, ¿ù°æÃâÇ÷, ºÐ¸¸ ÈÄ ÃâÇ÷ µîÀÌ ÇöÀúÈ÷ Áõ°¡ÇÑ´Ù..
  • wasting disease
    ¼Ò¸ðº´
  • weber christian disease
    ¿þ¹ö-Å©¸®½ºÂùº´
  • Weber-Christian disease °áÀý¼º, ºñÈ­³ó¼º, ÇÇÇÏ Áö¹æÁ¶Á÷ÀÇ ¿°Áõ.

    Weber-Cocayne syndrome

    ¿þ¹ö ÄÚÄÉÀÎ ÁõÈıº
    ±¹ÇѼºÀÇ Ç¥ÇÇ ¼öÆ÷Áõ.
  • Weil's disease Ȳ´Þ ÃâÇ÷¼º ·¾Å佺ÇǶóÁõ.

    Weinrich et Emmerson

    ¼è¼¼¸ðÆí¸ðÃæ
  • Werlhof disease
    º£¸¦È£ÇÁ º´
    ÇǺο¡ ÃâÇ÷À» º¼ ¼ö ÀÖ´Â Àڹݺ´ÀÇ Çϳª·Î¼­ Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º Àڹݺ´, ÃâÇ÷¼º Àڹݺ´À̶ó°íµµ ÇÑ´Ù. ÇǺγª Á¡¸·
  • wernicke's disease
    º£¸£´ÏÄɺ´
    µ¿ÀǾî=
  • whipple's disease Èí¼öºÎÀü ÁõÈıºÀ¸·Î ¼³»ç, Áö¹æ º¯Áõ, ÇǺλö¼Ò Ä§Âø, °üÀý¿°, °üÀýÅë, ¸²ÇÁÀý¿°, ÁßÃ߽Űæ°èÀå¾Ö°¡ Ư¡ÀÌ´Ù.

    Whipple's triad

    ÇÇÇþ¾ »ï¡ÈÄ
    ¿øÀο¡ °ü°è¾øÀÌ ¸ðµç ÀúÇ÷´çÁõÀÇ Æ¯Â¡À¸·Î 1
  • white finger disease
    ¹é¶øº´
    ¾ÐÃà°ø±â, ÇØ¸Ó, Àüµ¿ Åé µî ¼Õ¿¡ Áã°í Á¶ÀÛÇÏ´Â Áøµ¿°ø±¸ÀÇ Áøµ¿À¸·Î ¼ÕÀÇ µ¿¸ÆÀÌ Àå¾Ö¸¦ ¹Þ¾Æ °©Àڱ⠼հ¡¶ôÀÌ Ã¢¹éÇØÁö´Â º´. »çÁö ¸»´Ü, ƯÈ÷ ¼öÁöÀÇ Ç÷°üÀå¾Ö·Î ÁßÁõÀÏ ¶§´Â ȯºÎ°¡ ±«»ç¿¡ ºüÁö´Â Á÷¾÷º´À¸·Î ·¹À̳ë ÁõÈıºÀÇ ÇÑ º´ÇüÀ¸·Î °£ÁÖÇϰí ÀÖ´Ù. ¿øÀÎÀº Ç÷°ü ¿îµ¿ ½Å°æ Àå¾Ö·Î ÀÎÇÑ µ¿¸Æ ¼öÃà ¶§¹®¿¡ ÀϾ´Â Ç÷·ù Àå¾ÖÀÌ´Ù. Áõ¼¼´Â ¹ßÀÛÀûÀ¸·Î ÀϾ ¼Õ°¡¶ôÀÌ Ã¢¹éÇØÁö¸ç, ÅëÁõ°ú Àú¸®´Â °¨ÀÌ ÀÖ°í, ÀÌ¾î º¸¶ó»öÀ¸·Î º¯Çß´Ù°¡ ºÓ¾îÁö¸é¼­ ȸº¹µÇ¸ç, ÀÌ »çÀÌ´Â ¼öºÐ ³»Áö ¼ö ½Ê ºÐÀ̰í Ãß¿ï ¶§ ¸¹´Ù. Ä¡·á´Â Ç÷°üÈ®ÀåÁ¦¸¦ »ç¿ëÇÏ°í ¼ÕÀ» Â÷Áö ¾Ê°Ô º¸¿Â¿¡ ÁÖÀÇÇϸç, °ø±¸ »ç¿ëÀº ÀÏÁ¤ ±â°£ »ï°¡´Â °ÍÀÌ ÁÁ´Ù.
  • woolsorters disease
    ¾ç¸ð¾÷ÀÚº´
    ¾ç¸ð¸¦ Ãë±ÞÇÏ´Â »ç¶÷¿¡¼­ º¼ ¼ö ÀÖ´Â ÆóÀÇ ÅºÀú·Î, B. anthrax¸¦ ÈíÀÔÇÔÀ¸·Î½á ÀϾ´Ù.
  • Zahorsky's disease
    ÀÚÈ£¸£½ºÅ° º´
    À¯¾Æ¿¡¼­ º¼ ¼ö ÀÖ´Â µ¹¹ß¼º ¹ßÁø.
  • Ziehen-Oppengeim disease
    Á¦¿£-¿ÀÆæÇÏÀÓº´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
Pellegrini-Stieda disease A calcific density in the medial collateral ligament and/or bony growth at the internal condyle of the femur.
Synonym: Pellegrini-Stieda disease.
(05 Mar 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
von Economo's disease A unique encephalitis, presumably viral in origin, which followed the influenza pandemic of 1914-1918. Symptoms included ophthalmoplegia and marked somnolence, and in many survivors, the delayed development of Parkinson's disease; the basis for postencephalitic Parkinsonism.
Synonym: encephalitis lethargica, polioencephalitis infectiva.
(05 Mar 2000)
Von Gierke's disease <disease> A congenital disease caused by a metabolic error in which the body deposits an abnormally high amount of glycogen in the kidneys and liver, the disease produces symptoms such as hypoglycaemia (low blood sugar) and hyperlipaemia (an excess of lipid molecules in the blood, which can lead to problems such as clogged arteries and heart attacks).
(09 Oct 1997)
von hippel-lindau disease <disease> A congenital disease characterised by the development of blood vesse ltumours in the retina of the eye and in the brain, lesions and cysts canalso develop in the spina lcord, pancreas, kidneys, and other organs.
(09 Oct 1997)
pelvic imflammatory disease <disease> The inflammation of any of the female pelvic organs, usually due to infection from a sexually transmitted disease. PID can result in sterility if left untreated.
(09 Oct 1997)
pelvic inflammatory disease <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á